Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Demser Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy N/A

    Demser (metyrosine) Coverage Criteria

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and reauthorization for Demser (metyrosine) used to treat pheochromocytoma. It applies to providers seeking coverage for members under the applicable benefit plan.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyDemser (metyrosine) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionFor reauthorization, document a positive clinical response to Demser therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization period
    12 monthsReauthorization period
    1Covered medication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Pheochromocytoma
    Covered diagnosis

    Coverage Criteria

    Initial Authorization

    Covered when the following criterion is met:

    Initial authorization: Diagnosis of pheochromocytoma

    Reauthorization

    Covered when the following criterion is met:

    Reauthorization: Documentation of positive clinical response to therapy

    Documentation and Authorization Actions

    Prior Authorization

    Initial Authorization Diagnosis

    For initial authorization, document a diagnosis of pheochromocytoma.

    Documentation Required

    Reauthorization Response

    Reauthorization is issued for 12 months when documentation demonstrates a positive clinical response to Demser therapy.

    Documentation Required

    Document Positive Clinical Response

    To support continued Demser therapy, provide documentation of the patient’s positive clinical response to therapy.

    Medication Background

    Demser (metyrosine) is indicated for patients with pheochromocytoma who require preoperative preparation, management when surgery is contraindicated, or chronic treatment for malignant pheochromocytoma. Demser is not recommended for control of essential hypertension.

    Demser Initial Authorization

    Demser Initial Authorization

    Initial authorization is approved when the following criterion is met:

    Pheochromocytoma diagnosis: Diagnosis of pheochromocytoma

    Demser Reauthorization

    Demser Reauthorization

    Reauthorization is approved when the following criterion is met:

    Positive clinical response: Documentation of positive clinical response to therapy
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyDemser (metyrosine) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateN/A
    Key ActionFor reauthorization, document a positive clinical response to Demser therapy.
    SourceLink
    On This Page
    Coverage CriteriaDocumentation and Authorization ActionsMedication BackgroundDemser Initial AuthorizationDemser Reauthorization